Julian Assange hat heute um 16 Uhr ein Bitnik-Paket abgeschickt an den in Bahrain inhaftierten Nabell Rajab. In der Hülle des Pakets ist ein kleines Loch. Durch dieses Loch guckt eine Kamera. Und das sieht sie:

Hier ist das Paket im Moment:

Die Story ist jetzt auch auf der Startseite von wikileaks. Hier ein Interview, das Assange mit u.a. Nabeel führte vor gut einem Jahr:

Die Bitniks werden u.a. unterstützt in ihren Aktionen vom Migros-Kulturprozent. Berücksichtige die Tatsache vielleicht bei Deiner nächsten Wahl des Einkaufsortes :-)

Soeben haben wir die provisorischen Unterlagen des Börsenganges von Glycomimetics erhalten: GlycoMimetics eRed (application/pdf, 1.434 KB) . 164 Seiten Kleingedrucktes für Fans!

Die Uni Basel hatte im Jahresbericht 2011 geschrieben:

In einer neunjährigen Zusammenarbeit mit der amerikanischen Biotechfirma GlycoMimetics Inc. haben Prof. Ernst und sein Team am Pharmazentrum einen Wirkstoff entwickelt, der zurzeit klinisch getestet wird und auf gutem Weg ist, als Medikament zum Einsatz zu kommen. Das GMI-1070 genannte Glycomimetikum greift in Entzündungsprozesse ein, indem es ein Zuckermolekül imitiert, das bei Entzündungen mit Proteinen der Selectin-Familie interagiert. (...) Der Wirkstoff GMI-1070 befindet sich derzeit in Phase II der klinischen Entwicklung und wird an Patienten mit Sichelzellanämie getestet. Der US-Pharmakonzern Pfizer kaufte kürzlich die Lizenzrechte von GlycoMimetics für 350 Millionen US-Dollar und übernahm damit die Weiterentwicklung des vielversprechenden Wirkstoffs.

In den Unterlagen zum Börsengang erfahren wir aber jetzt Folgendes auf S. 48:

We have a research services agreement with the University of Basel, or the University, under which University personnel have performed research services for us on an as-requested basis since 2004. The agreement includes one-year research terms, and we have no affirmative obligation to purchase any minimum amount of services in any year beyond what we commit to at the beginning of each term, if any. For each of the research terms ended in February 2012 and 2013, we paid the University approximately $150,000. As part of the original consideration for entering into this agreement, we granted to the University the right to receive payments from us under specified circumstances. If we receive any future milestone payments or royalties from Pfizer with respect to GMI-1070, we have agreed to pay 10% of those amounts to the University.

Über die Zusammenarbeit mit Pfizer schreibt Glycomimetics auf S. 47:

Our Collaboration with Pfizer

In October 2011, we entered into the license agreement with Pfizer under which we granted Pfizer an exclusive worldwide license to develop and commercialize products containing GMI-1070 for all fields and uses. The license also covers specified back-up compounds along with modifications of and improvements to GMI-1070 that meet defined chemical properties. Pfizer is required to use commercially reasonable efforts, at its expense, to develop, obtain regulatory approval for and commercialize GMI-1070 for sickle cell disease in the United States. Under the terms of the agreement, we received a $22.5 million upfront payment. We are also eligible to earn potential milestone payments of up to $115.0 million upon the achievement of specified development milestones, including the dosing of the first patients in Phase 3 clinical trials for up to two indications and the first commercial sale of a licensed product in the United States and selected European countries for up to two indications, up to $70.0 million upon the achievement of specified regulatory milestones, including the acceptance of our filings for regulatory approval by regulatory authorities in the United States and Europe for up to two indications, and up to $135.0 million upon the achievement of specified levels of annual net sales of licensed products. We are also eligible to receive tiered royalties for each licensed product, with percentages ranging from the low double digits to the low teens, based on net sales worldwide, subject to reductions in specified circumstances.

The first potential milestone payment that we might be entitled to receive under the Pfizer agreement is $35.0 million upon the initiation of dosing of the first patient in a Phase 3 trial of GMI-1070 by Pfizer. In some specified circumstances, if Pfizer has not initiated dosing by April 2014, Pfizer is obligated to make an advance payment to us of $15.0 million against the first milestone payment.

Pfizer has advised us through the joint steering committee established under the agreement that they intend to begin enrolling patients for a Phase 3 trial of GMI-1070 in mid-2014, pending approval through Pfizer’s governance process. Pfizer has also informed us through the joint steering committee that activities necessary to support the initiation of a Phase 3 trial in mid-2014 are currently underway pending approval through Pfizer’s governance process. The steps that Pfizer has taken and is taking to prepare for a Phase 3 trial include manufacturing of the drug substance to be used in the Phase 3 trial, completion of toxicology studies that would support a Phase 3 trial and an NDA, engagement with regulatory authorities in the United States and overseas to discuss plans for the conduct of a Phase 3 trial, planning and preparation for a so-called TQTc clinical trial to evaluate cardiac safety that would support a Phase 3 trial, contracting with a CRO to provide services in the conduct of a Phase 3 trial and convening clinical investigators in the United States and overseas to discuss plans for a Phase 3 trial.

Although Pfizer has taken and is taking a number of steps to prepare for Phase 3 initiation in mid-2014, there can be no assurance that Pfizer will proceed on that schedule, or at all. There also can be no assurance that, if Pfizer does not initiate dosing by April 2014, the conditions to its obligation to make the $35.0 million milestone payment or the $15.0 million advance will be satisfied.

355 Millionen Dollar stehen Glycomimetics noch zu im Erfolgsfall. Und später weitere Lizenzgebühren aus den Verkäufen von Pfizer.

Das heisst weiter:

Im besten Fall erhält die Uni Basel von Glycomimetics rund 35 Millionen Dollar Erfolgsbeteiligung plus später 10% der Lizenzzahlungen von Pfizer.

Warum hat eigentlich die Uni Basel so ein Tamtam um die Zahlen gemacht? Das bleibt wohl weiterhin ihr Geheimnis…

Man trifft sich morgen Abend im "kult.kino atelier" um 18:30:

Es diskutieren: Beat Jans, Nationalrat; Charles McCombie, Nuklearphysiker und Protagonist; Marcos Buser, Geologe und Edgar Hagen, Regisseur. Moderation: Alfred Schlienger, Filmkritiker
.

Aber ein bisschen konfus macht es mich schon ...